This study highlights an important interaction between IL-17A and TLR3 signaling in excessive airway inflammation, and control of IL-17A/TLR3-mediated NF-κB/IRF3 activation may be a novel therapeutic target to prevent exacerbation of asthma. Here, NFKB1 is linked to asthma.